BMS-986012 + platinum + etoposide

BMS-986012 + platinum + etoposide is an experimental combination regimen for the treatment of extensive-stage small cell lung cancer (ES-SCLC). BMS-986012 is a first-in-class, fully human, non-fucosylated IgG1 monoclonal antibody designed to specifically target Fucosyl-GM1 (Fuc-GM1), a glycolipid highly expressed on most SCLC tumor cells and minimally on normal tissues. By binding Fuc-GM1, BMS-986012 mediates antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity, and antibody-dependent cellular phagocytosis, thereby enhancing immune system–mediated tumor cell death. Platinum (commonly carboplatin or cisplatin) and etoposide are cytotoxic chemotherapeutic agents widely used as standard of care in ES-SCLC, and act primarily by interfering with DNA replication and cell division. This combination is under clinical investigation to establish safety, tolerability, and efficacy in newly diagnosed, treatment-naïve patients with extensive-stage SCLC[1][2][4].